IGF2BP1 and hepatocellular carcinoma: Similarily, after confirmation of IGF2BP1 as a crucial regulator of T cell composition in the TIME of HCC, an IGF2BP1 small molecule inhibitor exhibited the ability to recruit not only CD4+ and CD8+ T cells, but also CD56+ NK cells and F4/80+ macrophage, into the TIME [136].